APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dermatology Drug

A dermatology drug is a medication used to prevent, diagnose, manage, and treat skin diseases and conditions. Skin diseases can include, but are not limited to, acne, psoriasis, eczema, dermatitis, fungal infections, viral infections (such as herpes zoster), and other skin abnormalities.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A dermatology drug is a medication used to prevent, diagnose, manage, and treat skin diseases and conditions. Skin diseases can include, but are not limited to, acne, psoriasis, eczema, dermatitis, fungal infections, viral infections (such as herpes zoster), and other skin abnormalities. These medications can be prescription or over-the-counter and can be administered in various forms such as oral, topical (creams, gels, ointments), and injectable.

Common types of dermatology drugs include:

a. Antibiotics: Used to treat bacterial infections, such as acne and cellulitis.

b. Antifungal agents: Used to treat fungal infections, such as ringworm and candidiasis.

c. Antiviral medications: Used to treat viral infections, such as shingles and warts.

d. Steroids: Used to reduce inflammation and allergic reactions, commonly used for eczema and psoriasis.

e. Immunomodulators: Used to modulate the immune system, such as tacrolimus and pimecrolimus.

f. Vitamin D analogs: Used to treat psoriasis, such as calcipotriene.

g. Keratolytics: Used to treat acne by promoting exfoliation, such as benzoyl peroxide and retinoids.

The research object may be an ingredient, device, preparation or care service. These supply stages have different specifications and measurement units; an ingredient identity or device name does not establish a clinical outcome.

What turns activity into demand

Qualified use at the specified treatment or instrument boundary creates purchases through protocol, utilisation and replacement. A product, clinical service and complete care episode measure different supplied objects.

The commercial boundary

For Dermatology Drug, distinguish the supplied product from its inputs and the complete application. Report types and applications may overlap; retain the selected edition's product definition, geography, period, unit and transaction basis when comparing estimates.

Which conditions determine usable dermatology drug performance?

A dermatology drug is a medication used to prevent, diagnose, manage, and treat skin diseases and conditions. Skin diseases can include, but are not limited to, acne, psoriasis, eczema, dermatitis, fungal infections, viral infections (such as herpes zoster), and other skin abnormalities. Confirm the specified composition or device function, intended use and supplied unit. Separate ingredients, finished preparations, equipment and treatment activity before comparing quantities or revenue; use the report scope rather than inferring efficacy from an illustration.

Selected research

Market Analysis & Forecast

Global Dermatology Drug Market Analysis and Forecast 2026-2032

21 December 2025213 pages

Choose your research edition.

Industry ResearchDermatology Drug Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Dermatology Drug Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Dermatology Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dermatology Drug Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Dermatology Drug Market Analysis and Forecast 2026-2032213 pages · $4,950 USD

Market perspective

A dermatology drug is a medication used to prevent, diagnose, manage, and treat skin diseases and conditions. Skin diseases can include, but are not limited to, acne, psoriasis, eczema, dermatitis, fungal infections, viral infections (such as herpes zoster), and other skin abnormalities. These medications can be prescription or over-the-counter and can be administered in various forms such as oral, topical (creams, gels, ointments), and injectable.

Common types of dermatology drugs include:

a. Antibiotics: Used to treat bacterial infections, such as acne and cellulitis.

Read the full market overview

b. Antifungal agents: Used to treat fungal infections, such as ringworm and candidiasis.

c. Antiviral medications: Used to treat viral infections, such as shingles and warts.

d. Steroids: Used to reduce inflammation and allergic reactions, commonly used for eczema and psoriasis.

e. Immunomodulators: Used to modulate the immune system, such as tacrolimus and pimecrolimus.

f. Vitamin D analogs: Used to treat psoriasis, such as calcipotriene.

g. Keratolytics: Used to treat acne by promoting exfoliation, such as benzoyl peroxide and retinoids.

The global Dermatology Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Dermatology Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Dermatology Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Asia-Pacific market for Dermatology Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Dermatology Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Dermatology Drug include AbbVie, Johnson & Johnson, Bayer, Galderma, Bristol-Myers Squibb, Novartis, Pfizer, Merz Pharma and Valeant, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Dermatology Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Dermatology Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Dermatology Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Dermatology Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Dermatology Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Dermatology Drug revenue, projected growth trends, production technology, application and end-user industry.

Dermatology Drug Segment by Company

AbbVie

Johnson & Johnson

Bayer

Galderma

Bristol-Myers Squibb

Novartis

Pfizer

Merz Pharma

Valeant

Leo Pharma A/S

GlaxoSmithKline (GSK)

Allergan

Almirall S.A.

Amgen

Astellas

Concert Pharmaceuticals

Eli Lilly and Company

Lupin

Mayne Pharma

Merck KGaA

AstraZeneca plc

Roivant Sciences (Dermavant Sciences)

Dermatology Drug Segment by Type

External Use

Oral

Injection

Dermatology Drug Segment by Application

Psoriasis

Skin Infections

Acne

Dermatitis

Others

Dermatology Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatology Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dermatology Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatology Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Dermatology Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Dermatology Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Dermatology Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Dermatology Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. External Use Major Player Table 3. Oral Major Player Table 4. Injection Major Player Table 5. Global Dermatology Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Psoriasis Major Player Table 7. Skin Infections Major Player Table 8. Acne Major Player Table 9. Dermatitis Major Player Table 10. Others Major Player Table 11. Dermatology Drug Industry Trends Table 12. Dermatology Drug Industry Drivers Table 13. Dermatology Drug Industry Opportunities and Challenges Table 14. Dermatology Drug Industry Restraints Table 15. Global Dermatology Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Dermatology Drug Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Dermatology Drug Market Share by Region (2021-2026) Table 18. Global Dermatology Drug Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Dermatology Drug Market Share by Region (2027-2032) Table 20. Global Dermatology Drug Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Dermatology Drug Revenue Market Share by Players (2021-2026) Table 22. Global Dermatology Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Dermatology Drug Key Players Headquarters & Area Served Table 24. Global Dermatology Drug Players, Product Type & Application Table 25. Global Dermatology Drug Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Dermatology Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Dermatology Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Dermatology Drug Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Dermatology Drug Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Dermatology Drug Revenue Market Share by Type (2021-2026) Table 32. Global Dermatology Drug Revenue Market Share by Type (2027-2032) Table 33. Global Dermatology Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Dermatology Drug Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Dermatology Drug Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Dermatology Drug Revenue Market Share by Application (2021-2026) Table 37. Global Dermatology Drug Revenue Market Share by Application (2027-2032) Table 38. AbbVie Company Information Table 39. AbbVie Business Overview Table 40. AbbVie Dermatology Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. AbbVie Dermatology Drug Product Portfolio Table 42. AbbVie Recent Development Table 43. Johnson & Johnson Company Information Table 44. Johnson & Johnson Business Overview Table 45. Johnson & Johnson Dermatology Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Johnson & Johnson Dermatology Drug Product Portfolio Table 47. Johnson & Johnson Recent Development Table 48. Bayer Company Information Table 49. Bayer Business Overview Table 50. Bayer Dermatology Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Bayer Dermatology Drug Product Portfolio Table 52. Bayer Recent Development Table 53. Galderma Company Information Table 54. Galderma Business Overview Table 55. Galderma Dermatology Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Galderma Dermatology Drug Product Portfolio Table 57. Galderma Recent Development Table 58. Bristol-Myers Squibb Company Information Table 59. Bristol-Myers Squibb Business Overview Table 60. Bristol-Myers Squibb Dermatology Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Bristol-Myers Squibb Dermatology Drug Product Portfolio Table 62. Bristol-Myers Squibb Recent Development Table 63. Novartis Company Information Table 64. Novartis Business Overview Table 65. Novartis Dermatology Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Novartis Dermatology Drug Product Portfolio Table 67. Novartis Recent Development Table 68. Pfizer Company Information Table 69. Pfizer Business Overview Table 70. Pfizer Dermatology Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Pfizer Dermatology Drug Product Portfolio Table 72. Pfizer Recent Development Table 73. Merz Pharma Company Information Table 74. Merz Pharma Business Overview Table 75. Merz Pharma Dermatology Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Merz Pharma Dermatology Drug Product Portfolio Table 77. Merz Pharma Recent Development Table 78. Valeant Company Information Table 79. Valeant Business Overview Table 80. Valeant Dermatology Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Valeant Dermatology Drug Product Portfolio Table 82. Valeant Recent Development Table 83. Leo Pharma A/S Company Information Table 84. Leo Pharma A/S Business Overview Table 85. Leo Pharma A/S Dermatology Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Leo Pharma A/S Dermatology Drug Product Portfolio Table 87. Leo Pharma A/S Recent Development Table 88. GlaxoSmithKline (GSK) Company Information Table 89. GlaxoSmithKline (GSK) Business Overview Table 90. GlaxoSmithKline (GSK) Dermatology Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. GlaxoSmithKline (GSK) Dermatology Drug Product Portfolio Table 92. GlaxoSmithKline (GSK) Recent Development Table 93. Allergan Company Information Table 94. Allergan Business Overview Table 95. Allergan Dermatology Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Allergan Dermatology Drug Product Portfolio Table 97. Allergan Recent Development Table 98. Almirall S.A. Company Information Table 99. Almirall S.A. Business Overview Table 100. Almirall S.A. Dermatology Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Almirall S.A. Dermatology Drug Product Portfolio Table 102. Almirall S.A. Recent Development Table 103. Amgen Company Information Table 104. Amgen Business Overview Table 105. Amgen Dermatology Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Amgen Dermatology Drug Product Portfolio Table 107. Amgen Recent Development Table 108. Astellas Company Information Table 109. Astellas Business Overview Table 110. Astellas Dermatology Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Astellas Dermatology Drug Product Portfolio Table 112. Astellas Recent Development Table 113. Concert Pharmaceuticals Company Information Table 114. Concert Pharmaceuticals Business Overview Table 115. Concert Pharmaceuticals Dermatology Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Concert Pharmaceuticals Dermatology Drug Product Portfolio Table 117. Concert Pharmaceuticals Recent Development Table 118. Eli Lilly and Company Company Information Table 119. Eli Lilly and Company Business Overview Table 120. Eli Lilly and Company Dermatology Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Eli Lilly and Company Dermatology Drug Product Portfolio Table 122. Eli Lilly and Company Recent Development Table 123. Lupin Company Information Table 124. Lupin Business Overview Table 125. Lupin Dermatology Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Lupin Dermatology Drug Product Portfolio Table 127. Lupin Recent Development Table 128. Mayne Pharma Company Information Table 129. Mayne Pharma Business Overview Table 130. Mayne Pharma Dermatology Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Mayne Pharma Dermatology Drug Product Portfolio Table 132. Mayne Pharma Recent Development Table 133. Merck KGaA Company Information Table 134. Merck KGaA Business Overview Table 135. Merck KGaA Dermatology Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Merck KGaA Dermatology Drug Product Portfolio Table 137. Merck KGaA Recent Development Table 138. AstraZeneca plc Company Information Table 139. AstraZeneca plc Business Overview Table 140. AstraZeneca plc Dermatology Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. AstraZeneca plc Dermatology Drug Product Portfolio Table 142. AstraZeneca plc Recent Development Table 143. Roivant Sciences (Dermavant Sciences) Company Information Table 144. Roivant Sciences (Dermavant Sciences) Business Overview Table 145. Roivant Sciences (Dermavant Sciences) Dermatology Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Roivant Sciences (Dermavant Sciences) Dermatology Drug Product Portfolio Table 147. Roivant Sciences (Dermavant Sciences) Recent Development Table 148. North America Dermatology Drug Revenue by Type (2021-2026) & (US$ Million) Table 149. North America Dermatology Drug Revenue by Type (2027-2032) & (US$ Million) Table 150. North America Dermatology Drug Revenue by Application (2021-2026) & (US$ Million) Table 151. North America Dermatology Drug Revenue by Application (2027-2032) & (US$ Million) Table 152. North America Dermatology Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 153. North America Dermatology Drug Revenue by Country (2021-2026) & (US$ Million) Table 154. North America Dermatology Drug Revenue by Country (US$ Million) & (2027-2032) Table 155. Europe Dermatology Drug Revenue by Type (2021-2026) & (US$ Million) Table 156. Europe Dermatology Drug Revenue by Type (2027-2032) & (US$ Million) Table 157. Europe Dermatology Drug Revenue by Application (2021-2026) & (US$ Million) Table 158. Europe Dermatology Drug Revenue by Application (2027-2032) & (US$ Million) Table 159. Europe Dermatology Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 160. Europe Dermatology Drug Revenue by Country (2021-2026) & (US$ Million) Table 161. Europe Dermatology Drug Revenue by Country (US$ Million) & (2027-2032) Table 162. China Dermatology Drug Revenue by Type (2021-2026) & (US$ Million) Table 163. China Dermatology Drug Revenue by Type (2027-2032) & (US$ Million) Table 164. China Dermatology Drug Revenue by Application (2021-2026) & (US$ Million) Table 165. China Dermatology Drug Revenue by Application (2027-2032) & (US$ Million) Table 166. Asia Dermatology Drug Revenue by Type (2021-2026) & (US$ Million) Table 167. Asia Dermatology Drug Revenue by Type (2027-2032) & (US$ Million) Table 168. Asia Dermatology Drug Revenue by Application (2021-2026) & (US$ Million) Table 169. Asia Dermatology Drug Revenue by Application (2027-2032) & (US$ Million) Table 170. Asia Dermatology Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 171. Asia Dermatology Drug Revenue by Region (US$ Million) & (2021-2026) Table 172. Asia Dermatology Drug Revenue by Region (US$ Million) & (2027-2032) Table 173. SAMEA Dermatology Drug Revenue by Type (2021-2026) & (US$ Million) Table 174. SAMEA Dermatology Drug Revenue by Type (2027-2032) & (US$ Million) Table 175. SAMEA Dermatology Drug Revenue by Application (2021-2026) & (US$ Million) Table 176. SAMEA Dermatology Drug Revenue by Application (2027-2032) & (US$ Million) Table 177. SAMEA Dermatology Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 178. SAMEA Dermatology Drug Revenue by Country (2021-2026) & (US$ Million) Table 179. SAMEA Dermatology Drug Revenue by Country (US$ Million) & (2027-2032) Table 180. Research Programs/Design for This Report Table 181. Authors List of This Report Table 182. Secondary Sources Table 183. Primary Sources List of Figures Figure 1. Dermatology Drug Image Figure 2. Global Dermatology Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dermatology Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. External Use Image Figure 5. Oral Image Figure 6. Injection Image Figure 7. Global Dermatology Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Dermatology Drug Market Size Share 2021 VS 2025 VS 2032 Figure 9. Psoriasis Image Figure 10. Skin Infections Image Figure 11. Acne Image Figure 12. Dermatitis Image Figure 13. Others Image Figure 14. Global Dermatology Drug Market Size (US$ Million) & (2021-2032) Figure 15. Global Dermatology Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Dermatology Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Dermatology Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Dermatology Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Dermatology Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Dermatology Drug Revenue Market Share by Type (2021-2032) Figure 22. Global Dermatology Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Dermatology Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Dermatology Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Dermatology Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Dermatology Drug Revenue Share by Type (2021-2032) Figure 27. North America Dermatology Drug Revenue Share by Application (2021-2032) Figure 28. North America Dermatology Drug Revenue Share by Country (2021-2032) Figure 29. United States Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Dermatology Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Dermatology Drug Revenue Share by Type (2021-2032) Figure 34. Europe Dermatology Drug Revenue Share by Application (2021-2032) Figure 35. Europe Dermatology Drug Revenue Share by Country (2021-2032) Figure 36. Germany Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Dermatology Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Dermatology Drug Revenue Share by Type (2021-2032) Figure 46. China Dermatology Drug Revenue Share by Application (2021-2032) Figure 47. Asia Dermatology Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Dermatology Drug Revenue Share by Type (2021-2032) Figure 49. Asia Dermatology Drug Revenue Share by Application (2021-2032) Figure 50. Asia Dermatology Drug Revenue Share by Region (2021-2032) Figure 51. Japan Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Dermatology Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Dermatology Drug Revenue Share by Type (2021-2032) Figure 59. SAMEA Dermatology Drug Revenue Share by Application (2021-2032) Figure 60. SAMEA Dermatology Drug Revenue Share by Country (2021-2032) Figure 61. Brazil Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Dermatology Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • External Use
  • Oral
  • Injection
Applications
  • Psoriasis
  • Skin Infections
  • Acne
  • Dermatitis
  • Others
Companies covered
  • AbbVie
  • Johnson & Johnson
  • Bayer
  • Galderma
  • Bristol-Myers Squibb
  • Novartis
  • Pfizer
  • Merz Pharma
  • Valeant
  • Leo Pharma A/S
  • GlaxoSmithKline (GSK)
  • Allergan
  • Almirall S.A.
  • Amgen
  • Astellas
  • Concert Pharmaceuticals
  • Eli Lilly and Company
  • Lupin
  • Mayne Pharma
  • Merck KGaA
  • AstraZeneca plc
  • Roivant Sciences (Dermavant Sciences)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Dermatology Drug Market by Type
  3. 1.2.1 Global Dermatology Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 External Use
  5. 1.2.3 Oral
  6. 1.2.4 Injection
  7. 1.3 Dermatology Drug Market by Application
  8. 1.3.1 Global Dermatology Drug Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Psoriasis
  10. 1.3.3 Skin Infections
  11. 1.3.4 Acne
  12. 1.3.5 Dermatitis
  13. 1.3.6 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Dermatology Drug Market Dynamics
  1. 2.1 Dermatology Drug Industry Trends
  2. 2.2 Dermatology Drug Industry Drivers
  3. 2.3 Dermatology Drug Industry Opportunities and Challenges
  4. 2.4 Dermatology Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Dermatology Drug Market Perspective (2021-2032)
  2. 3.2 Global Dermatology Drug Growth Trends by Region
  3. 3.2.1 Global Dermatology Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Dermatology Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Dermatology Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Dermatology Drug Revenue by Players
  2. 4.1.1 Global Dermatology Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Dermatology Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Dermatology Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Dermatology Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Dermatology Drug Key Players Headquarters & Area Served
  7. 4.4 Global Dermatology Drug Players, Product Type & Application
  8. 4.5 Global Dermatology Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Dermatology Drug Market CR5 and HHI
  11. 4.6.3 2025 Dermatology Drug Tier 1, Tier 2, and Tier 3
5 Dermatology Drug Market Size by Type
  1. 5.1 Global Dermatology Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Dermatology Drug Revenue by Type (2021-2032)
  3. 5.3 Global Dermatology Drug Revenue Market Share by Type (2021-2032)
6 Dermatology Drug Market Size by Application
  1. 6.1 Global Dermatology Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Dermatology Drug Revenue by Application (2021-2032)
  3. 6.3 Global Dermatology Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 AbbVie
  2. 7.1.1 AbbVie Company Information
  3. 7.1.2 AbbVie Business Overview
  4. 7.1.3 AbbVie Dermatology Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 AbbVie Dermatology Drug Product Portfolio
  6. 7.1.5 AbbVie Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Dermatology Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Dermatology Drug Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Bayer
  14. 7.3.1 Bayer Company Information
  15. 7.3.2 Bayer Business Overview
  16. 7.3.3 Bayer Dermatology Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bayer Dermatology Drug Product Portfolio
  18. 7.3.5 Bayer Recent Developments
  19. 7.4 Galderma
  20. 7.4.1 Galderma Company Information
  21. 7.4.2 Galderma Business Overview
  22. 7.4.3 Galderma Dermatology Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Galderma Dermatology Drug Product Portfolio
  24. 7.4.5 Galderma Recent Developments
  25. 7.5 Bristol-Myers Squibb
  26. 7.5.1 Bristol-Myers Squibb Company Information
  27. 7.5.2 Bristol-Myers Squibb Business Overview
  28. 7.5.3 Bristol-Myers Squibb Dermatology Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bristol-Myers Squibb Dermatology Drug Product Portfolio
  30. 7.5.5 Bristol-Myers Squibb Recent Developments
  31. 7.6 Novartis
  32. 7.6.1 Novartis Company Information
  33. 7.6.2 Novartis Business Overview
  34. 7.6.3 Novartis Dermatology Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Novartis Dermatology Drug Product Portfolio
  36. 7.6.5 Novartis Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Dermatology Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Dermatology Drug Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 Merz Pharma
  44. 7.8.1 Merz Pharma Company Information
  45. 7.8.2 Merz Pharma Business Overview
  46. 7.8.3 Merz Pharma Dermatology Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Merz Pharma Dermatology Drug Product Portfolio
  48. 7.8.5 Merz Pharma Recent Developments
  49. 7.9 Valeant
  50. 7.9.1 Valeant Company Information
  51. 7.9.2 Valeant Business Overview
  52. 7.9.3 Valeant Dermatology Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Valeant Dermatology Drug Product Portfolio
  54. 7.9.5 Valeant Recent Developments
  55. 7.10 Leo Pharma A/S
  56. 7.10.1 Leo Pharma A/S Company Information
  57. 7.10.2 Leo Pharma A/S Business Overview
  58. 7.10.3 Leo Pharma A/S Dermatology Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Leo Pharma A/S Dermatology Drug Product Portfolio
  60. 7.10.5 Leo Pharma A/S Recent Developments
  61. 7.11 GlaxoSmithKline (GSK)
  62. 7.11.1 GlaxoSmithKline (GSK) Company Information
  63. 7.11.2 GlaxoSmithKline (GSK) Business Overview
  64. 7.11.3 GlaxoSmithKline (GSK) Dermatology Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 GlaxoSmithKline (GSK) Dermatology Drug Product Portfolio
  66. 7.11.5 GlaxoSmithKline (GSK) Recent Developments
  67. 7.12 Allergan
  68. 7.12.1 Allergan Company Information
  69. 7.12.2 Allergan Business Overview
  70. 7.12.3 Allergan Dermatology Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Allergan Dermatology Drug Product Portfolio
  72. 7.12.5 Allergan Recent Developments
  73. 7.13 Almirall S.A.
  74. 7.13.1 Almirall S.A. Company Information
  75. 7.13.2 Almirall S.A. Business Overview
  76. 7.13.3 Almirall S.A. Dermatology Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Almirall S.A. Dermatology Drug Product Portfolio
  78. 7.13.5 Almirall S.A. Recent Developments
  79. 7.14 Amgen
  80. 7.14.1 Amgen Company Information
  81. 7.14.2 Amgen Business Overview
  82. 7.14.3 Amgen Dermatology Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Amgen Dermatology Drug Product Portfolio
  84. 7.14.5 Amgen Recent Developments
  85. 7.15 Astellas
  86. 7.15.1 Astellas Company Information
  87. 7.15.2 Astellas Business Overview
  88. 7.15.3 Astellas Dermatology Drug Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Astellas Dermatology Drug Product Portfolio
  90. 7.15.5 Astellas Recent Developments
  91. 7.16 Concert Pharmaceuticals
  92. 7.16.1 Concert Pharmaceuticals Company Information
  93. 7.16.2 Concert Pharmaceuticals Business Overview
  94. 7.16.3 Concert Pharmaceuticals Dermatology Drug Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Concert Pharmaceuticals Dermatology Drug Product Portfolio
  96. 7.16.5 Concert Pharmaceuticals Recent Developments
  97. 7.17 Eli Lilly and Company
  98. 7.17.1 Eli Lilly and Company Company Information
  99. 7.17.2 Eli Lilly and Company Business Overview
  100. 7.17.3 Eli Lilly and Company Dermatology Drug Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Eli Lilly and Company Dermatology Drug Product Portfolio
  102. 7.17.5 Eli Lilly and Company Recent Developments
  103. 7.18 Lupin
  104. 7.18.1 Lupin Company Information
  105. 7.18.2 Lupin Business Overview
  106. 7.18.3 Lupin Dermatology Drug Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Lupin Dermatology Drug Product Portfolio
  108. 7.18.5 Lupin Recent Developments
  109. 7.19 Mayne Pharma
  110. 7.19.1 Mayne Pharma Company Information
  111. 7.19.2 Mayne Pharma Business Overview
  112. 7.19.3 Mayne Pharma Dermatology Drug Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Mayne Pharma Dermatology Drug Product Portfolio
  114. 7.19.5 Mayne Pharma Recent Developments
  115. 7.20 Merck KGaA
  116. 7.20.1 Merck KGaA Company Information
  117. 7.20.2 Merck KGaA Business Overview
  118. 7.20.3 Merck KGaA Dermatology Drug Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Merck KGaA Dermatology Drug Product Portfolio
  120. 7.20.5 Merck KGaA Recent Developments
  121. 7.21 AstraZeneca plc
  122. 7.21.1 AstraZeneca plc Company Information
  123. 7.21.2 AstraZeneca plc Business Overview
  124. 7.21.3 AstraZeneca plc Dermatology Drug Revenue and Gross Margin (2021-2026)
  125. 7.21.4 AstraZeneca plc Dermatology Drug Product Portfolio
  126. 7.21.5 AstraZeneca plc Recent Developments
  127. 7.22 Roivant Sciences (Dermavant Sciences)
  128. 7.22.1 Roivant Sciences (Dermavant Sciences) Company Information
  129. 7.22.2 Roivant Sciences (Dermavant Sciences) Business Overview
  130. 7.22.3 Roivant Sciences (Dermavant Sciences) Dermatology Drug Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Roivant Sciences (Dermavant Sciences) Dermatology Drug Product Portfolio
  132. 7.22.5 Roivant Sciences (Dermavant Sciences) Recent Developments
8 North America
  1. 8.1 North America Dermatology Drug Revenue (2021-2032)
  2. 8.2 North America Dermatology Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Dermatology Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Dermatology Drug Revenue by Type (2027-2032)
  5. 8.3 North America Dermatology Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Dermatology Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Dermatology Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Dermatology Drug Revenue by Application (2027-2032)
  9. 8.5 North America Dermatology Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Dermatology Drug Revenue by Country
  11. 8.6.1 North America Dermatology Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Dermatology Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Dermatology Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Dermatology Drug Revenue (2021-2032)
  2. 9.2 Europe Dermatology Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Dermatology Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Dermatology Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Dermatology Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Dermatology Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Dermatology Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Dermatology Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Dermatology Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Dermatology Drug Revenue by Country
  11. 9.6.1 Europe Dermatology Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Dermatology Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Dermatology Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Dermatology Drug Revenue (2021-2032)
  2. 10.2 China Dermatology Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Dermatology Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Dermatology Drug Revenue by Type (2027-2032)
  5. 10.3 China Dermatology Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Dermatology Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Dermatology Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Dermatology Drug Revenue by Application (2027-2032)
  9. 10.5 China Dermatology Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Dermatology Drug Revenue (2021-2032)
  2. 11.2 Asia Dermatology Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Dermatology Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Dermatology Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Dermatology Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Dermatology Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Dermatology Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Dermatology Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Dermatology Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Dermatology Drug Revenue by Country
  11. 11.6.1 Asia Dermatology Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Dermatology Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Dermatology Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Dermatology Drug Revenue (2021-2032)
  2. 12.2 SAMEA Dermatology Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Dermatology Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Dermatology Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Dermatology Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Dermatology Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Dermatology Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Dermatology Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Dermatology Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Dermatology Drug Revenue by Country
  11. 12.6.1 SAMEA Dermatology Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Dermatology Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Dermatology Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst